Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>United Therapeutics Corporation's third-quarter results for 2025 demonstrate both the company's operational strengths and challenges.</li><li>United Therapeutics reported record revenues of $800 million, up 7% from the same period in 2024, largely driven by increased demand for Tyvaso and Orenitram, key therapies in their portfolio addressing pulmonary hypertension (PH) and interstitial lung diseases.</li><li>This revenue growth is indicative of the effectiveness of their commercial strategies and market execution, underscoring the resilience of their business model despite increased competition.</li></ul>

United Therapeutics Corporation's third-quarter results for 2025 demonstrate both the company's operational strengths and challenges.United Therapeutics reported record revenues of $800 million, up 7% from the same period in 2024, largely driven by increased demand for Tyvaso and Orenitram, key therapies in their portfolio addressing pulmonary hypertension (PH) and interstitial lung diseases.This revenue growth is indicative of the effectiveness of their commercial strategies and market execution, underscoring the resilience of their business model despite increased competition.

United Therapeutics Eyes Billion-Dollar IPF Market—Can They Pull It Off?

<ul><li>United Therapeutics Corporation's second quarter 2025 results showcase a continuation of its strategic momentum, marked by 12 consecutive quarters of double-digit year-over-year revenue growth.</li><li>Total quarterly revenue reached a record $799 million, representing 12% growth from the same period in 2024.</li><li>The Tyvaso franchise, notably Tyvaso DPI, was a standout performer, achieving $315 million in total revenue, a 22% increase.</li></ul>

United Therapeutics Corporation's second quarter 2025 results showcase a continuation of its strategic momentum, marked by 12 consecutive quarters of double-digit year-over-year revenue growth.Total quarterly revenue reached a record $799 million, representing 12% growth from the same period in 2024.The Tyvaso franchise, notably Tyvaso DPI, was a standout performer, achieving $315 million in total revenue, a 22% increase.

United Therapeutics: The Top 6 Influences on Its Performance for 2025 & The Future!

<ul><li>United Therapeutics Corporation (United Therapeutics) reported a strong performance in the first quarter of 2025 with record revenue of $794 million, marking a 17% increase compared to the same period in 2024.</li><li>The company's commercial success continues to be driven by its key products: Tyvaso, Orenitram, Remodulin, and Unituxin, all of which have demonstrated consistent growth due to robust patient demand and increased prescriber engagement.</li><li>Tyvaso products, both the DPI (dry powder inhaler) and nebulizer forms, have shown significant market penetration, effectively contributing to the company's revenue and hinting at an optimistic future outlook.</li></ul>

United Therapeutics Corporation (United Therapeutics) reported a strong performance in the first quarter of 2025 with record revenue of $794 million, marking a 17% increase compared to the same period in 2024.The company's commercial success continues to be driven by its key products: Tyvaso, Orenitram, Remodulin, and Unituxin, all of which have demonstrated consistent growth due to robust patient demand and increased prescriber engagement.Tyvaso products, both the DPI (dry powder inhaler) and nebulizer forms, have shown significant market penetration, effectively contributing to the company's revenue and hinting at an optimistic future outlook.

United Therapeutics: Expansion into Organ Xenotransplantation to Position Itself As A Pioneer In This Emerging Domain!

<ul><li>United Therapeutics Corporation delivered a strong financial and developmental performance in the fourth quarter of 2024.</li><li>The company reported a record-setting year for revenue, which marked the third consecutive year of such accomplishment.</li><li>This performance was anchored by the robust growth of its treprostinil-based therapies, including Tyvaso, Orenitram, and Unituxin.</li></ul>

United Therapeutics Corporation delivered a strong financial and developmental performance in the fourth quarter of 2024.The company reported a record-setting year for revenue, which marked the third consecutive year of such accomplishment.This performance was anchored by the robust growth of its treprostinil-based therapies, including Tyvaso, Orenitram, and Unituxin.

United Therapeutics Corporation: Expansion in Tyvaso To Build A Robust Foundation For Sustained Revenue!

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>We downgraded our near-term outlook on SPX and QQQ to neutral last week (11/19/25), after being bullish since 4/22/25, while we maintained our intermediate-term bullish outlook (as of 5/14/25).</li>
<li>Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are back to being near-term bullish as long as these supports continue to hold</li>
<li>The latest pullback offers an attractive entry point into all the speculative growth areas that we were pounding the table on since May, WITH A STOP AT LAST WEEKS LOWS</li>
</ul>


We downgraded our near-term outlook on SPX and QQQ to neutral last week (11/19/25), after being bullish since 4/22/25, while we maintained our intermediate-term bullish outlook (as of 5/14/25).
Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are back to being near-term bullish as long as these supports continue to hold
The latest pullback offers an attractive entry point into all the speculative growth areas that we were pounding the table on since May, WITH A STOP AT LAST WEEKS LOWS


Back to Near-Term Bullish on SPX and Nasdaq 100; Supports Held at SPX 6480-6520 and QQQ $580-583

United States

United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease.  The Company's lead products are stable synthetic forms of prostacyclin and are delivered orally or subcutaneously.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

United Therapeutics (UTHR US)

United Therapeutics Eyes Billion-Dollar IPF Market—Can They Pull It Off?

United Therapeutics Corporation's third-quarter results for 2025 demonstrate both the company's operational strengths and challenges. United...

Baptista Research

United Therapeutics: The Top 6 Influences on Its Performance for 2025 & The Future!

United Therapeutics Corporation's second quarter 2025 results showcase a continuation of its strategic momentum, marked by 12 consecutive quarters...

Baptista Research

United Therapeutics: Expansion into Organ Xenotransplantation to Position Itself As A Pioneer In This Emerging Domain!

United Therapeutics Corporation (United Therapeutics) reported a strong performance in the first quarter of 2025 with record revenue of $794...

Baptista Research

United Therapeutics Corporation: Expansion in Tyvaso To Build A Robust Foundation For Sustained Revenue!

United Therapeutics Corporation delivered a strong financial and developmental performance in the fourth quarter of 2024. The company reported a...

Baptista Research

Back to Near-Term Bullish on SPX and Nasdaq 100; Supports Held at SPX 6480-6520 and QQQ $580-583

Back to Near-Term Bullish on $SPX and Nasdaq 100 $NDX; Crucial Supports Held at 6480-6520 on SPX and $580-$583 on $QQQ, we are near-term bullish as...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)